000118791 001__ 118791
000118791 005__ 20230519145541.0
000118791 0247_ $$2doi$$a10.3390/nu13041253
000118791 0248_ $$2sideral$$a126920
000118791 037__ $$aART-2021-126920
000118791 041__ $$aeng
000118791 100__ $$aGarcía-Layana A.
000118791 245__ $$aA randomized study of nutritional supplementation in patients with unilateral wet age-related macular degeneration
000118791 260__ $$c2021
000118791 5060_ $$aAccess copy available to the general public$$fUnrestricted
000118791 5203_ $$aThe purpose of this study is evaluate the efficacy and safety of medicinal products con-taining the original Age-Related Eye Disease group (AREDS) formulation at doses approved in Europe (EU, control group; n = 59) with a product that adds DHA, lutein, zeaxanthin, resveratrol and hydroxytyrosol to the formula (intervention group; n = 50). This was a multicenter, random-ized, observer-blinded trial conducted in patients aged 50 years or older diagnosed with unilateral exudative Age related Macular Degeneration AMD. At month 12, the intervention did not have a significant differential effect on visual acuity compared with the control group, with an estimated treatment difference in Early Treatment Diabetic Retinopathy Study (ETDRS) of -1.63 (95% CI -0.83 to 4.09; p = 0.192). The intervention exhibited a significant and, in most cases, relevant effect in terms of a reduction in some inflammatory cytokines and a greater improvement in the fatty acid profile and serum lutein and zeaxantin concentration. In patients with unilateral wet AMD, the addition of lutein, zeaxanthin, resveratrol, hydroxytyrosol and DHA to the AREDS EU recommended doses in the short-term did not have a differential effect on visual acuity compared to a standard AREDS EU formula but, in addition to improving the fatty acid profile and increasing carotenoid serum levels, may provide a beneficial effect in improving the proinflammatory and proangiogenic profile of patients with AMD. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
000118791 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000118791 590__ $$a6.706$$b2021
000118791 591__ $$aNUTRITION & DIETETICS$$b15 / 90 = 0.167$$c2021$$dQ1$$eT1
000118791 592__ $$a1.287$$b2021
000118791 593__ $$aNutrition and Dietetics$$c2021$$dQ1
000118791 593__ $$aFood Science$$c2021$$dQ1
000118791 594__ $$a7.9$$b2021
000118791 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000118791 700__ $$aRecalde S.
000118791 700__ $$aHernandez M.
000118791 700__ $$aAbraldes M.J.
000118791 700__ $$aNascimento J.
000118791 700__ $$aHernández-Galilea E.
000118791 700__ $$aOlmedilla-Alonso B.
000118791 700__ $$aEscobar-Barranco J.J.
000118791 700__ $$aZapata M.A.
000118791 700__ $$aSilva R.
000118791 700__ $$aArredondo M.C.
000118791 700__ $$aLopez-Sabater M.C.
000118791 700__ $$0(orcid)0000-0001-6072-1545$$aMendez-Martínez, S.$$uUniversidad de Zaragoza
000118791 700__ $$aPardiñas-Barón, N.$$uUniversidad de Zaragoza
000118791 700__ $$0(orcid)0000-0002-6202-2382$$aCalvo, P.
000118791 700__ $$aFernández-Robredo P.
000118791 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000118791 7102_ $$11013$$2646$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Oftalmología
000118791 773__ $$g13, 4 (2021), 1253 [16 pp]$$pNutrients$$tNutrients$$x2072-6643
000118791 8564_ $$s1232169$$uhttps://zaguan.unizar.es/record/118791/files/texto_completo.pdf$$yVersión publicada
000118791 8564_ $$s2920752$$uhttps://zaguan.unizar.es/record/118791/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000118791 909CO $$ooai:zaguan.unizar.es:118791$$particulos$$pdriver
000118791 951__ $$a2023-05-18-15:40:28
000118791 980__ $$aARTICLE